Prosight Management’s Immunovant IMVT Stock Holding History

Prosight Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.37M	Sell	175,825 -67,579	-28%	-$1.75M	0.72%	27
2025 Q4	$6.19M	Sell	243,404 -455,068	-65%	-$10.1M	1.28%	24
2025 Q3	$11.3M	Buy	698,472 +219,072	+46%	+$3.55M	2.63%	18
2025 Q2	$7.67M	Buy	479,400 +119,400	+33%	+$1.81M	1.87%	18
2025 Q1	$6.15M	Buy	360,000 +54,477	+18%	+$1.14M	2.02%	21
2024 Q4	$7.57M	Sell	305,523 -64,477	-17%	-$1.83M	2.09%	19
2024 Q3	$10.5M	Buy	370,000 +45,000	+14%	+$1.33M	2.6%	17
2024 Q2	$8.58M	Buy	325,000 +130,000	+67%	+$3.7M	2.56%	14
2024 Q1	$6.3M	Buy	+195,000	New	+$7.11M	1.75%	17
2020 Q3	–	Sell	-95,500	Closed	-$2.33M	–	53
2020 Q2	$2.33M	Sell	95,500 -25,929	-21%	-$556K	1%	29
2020 Q1	$1.89M	Sell	121,429 -103,273	-46%	-$1.55M	0.88%	29
2019 Q4	$3.57M	Buy	+224,702	New	+$2.52M	1.57%	20

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Prosight Management's IMVT Position: Q1 2026 in Review

Prosight Management reduced its Immunovant (IMVT) stake by 28% in Q1 2026, selling an estimated $1.75M and leaving 175,825 shares worth $4.37M. The position accounts for 0.72% of the portfolio, ranked #27.

Prosight Management first reported a position in IMVT in Q4 2019 and has held it in 12 quarters since. The position peaked at $11.3M in Q3 2025. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

Prosight Management held 175,825 shares of Immunovant worth $4.37M as of Q1 2026.
Prosight Management sold 67,579 Immunovant shares in Q1 2026, an estimated $1.75M.
Immunovant made up 0.72% of Prosight Management's portfolio in Q1 2026, its #27 holding.
Prosight Management first reported a position in Immunovant in Q4 2019 and has held it in 12 quarters since.
Prosight Management's Immunovant position peaked at $11.3M in Q3 2025.
215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Prosight Management's 13F filing for Q1 2026, filed 15 May 2026.